{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:30:43Z","timestamp":1787005843823,"version":"build-2736575974"},"reference-count":149,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Topical biological agents represent a significant advancement in the treatment of ocular surface diseases, offering a regenerative and therapeutic approach beyond conventional therapies. These agents are derived from serum (autologous or allogeneic), platelets, amniotic membrane, and pooled intravenous immunoglobulin. Their efficacy stems from their rich composition of growth factors, cytokines, and anti-inflammatory molecules that promote tissue healing, reduce inflammation, and enhance corneal regeneration. Autologous serum eye drops, closely mimicking natural tears, have been widely utilized for conditions such as dry eye disease, neurotrophic keratopathy, and persistent epithelial defects. Similarly, platelet derivatives, including platelet-rich plasma (PRP) and platelet lysate (PL), have demonstrated accelerated wound healing and nerve regeneration benefits. Amniotic membrane extracts and human amniotic fluid eye drops share the anti-inflammatory and regenerative properties of the human amniotic membrane. Recent advancements have introduced the use of topical IVIG, which modulates immune responses in severe inflammatory dry eye conditions, such as ocular graft-versus-host disease. Despite these promising applications, challenges such as variability in preparation, storage limitations, and cost remain. Nevertheless, the future of topical biological agents is promising, with emerging recombinant therapies and personalized treatment approaches shaping modern ophthalmologic care. As research continues to expand, these agents are poised to become integral components in managing ocular surface disorders, improving patient outcomes, and reducing dependence on traditional therapies.<\/jats:p>","DOI":"10.4103\/ijo.ijo_482_25","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T09:00:44Z","timestamp":1743325244000},"page":"496-507","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Biological topicals in ocular surface disorders"],"prefix":"10.4103","volume":"73","author":[{"given":"Sridevi","family":"Nair","sequence":"first","affiliation":[{"name":"Cornea, Cataract and Refractive Surgery Services, Dr R P Centre, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murugesan","family":"Vanathi","sequence":"additional","affiliation":[{"name":"Cornea, Cataract and Refractive Surgery Services, Dr R P Centre, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Tandon","sequence":"additional","affiliation":[{"name":"Cornea, Cataract and Refractive Surgery Services, Dr R P Centre, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"1478.","DOI":"10.3390\/jcm8091478","article-title":"Blood-based treatments for severe dry eye disease: The need of a consensus","volume":"8","author":"Bernabei","year":"2019","journal-title":"J Clin Med"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/ICO.0000000000002943","article-title":"Short-term efficacy and safety of biological tear substitutes and topical secretagogues for dry eye disease: A systematic review and network meta-analysis","volume":"41","author":"Jongkhajornpong","year":"2022","journal-title":"Cornea"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.transci.2017.07.023","article-title":"Blood derived eye drops for the treatment of cornea and ocular surface diseases","volume":"56","author":"Giannaccare","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.2147\/OPTH.S265701","article-title":"Human platelets and derived products in treating ocular surface diseases - A systematic review","volume":"14","author":"You","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"1500160.","DOI":"10.3389\/fmed.2024.1500160","article-title":"Blood component therapy for dry eye disease: A systematic review and network meta-analysis","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R6-20260422","article-title":"Spotlight on amniotic membrane extract eye drops: A review of the literature","author":"Kilian","year":"2024","journal-title":"Eye Contact Lens"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtos.2019.10.004","article-title":"Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease","volume":"18","author":"Kwon","year":"2020","journal-title":"Ocul Surf"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1542-0124(12)70613-4","article-title":"Growth factors in the tear film: Role in tissue maintenance, wound healing, and ocular pathology","volume":"5","author":"Klenkler","year":"2007","journal-title":"Ocul Surf"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archopht.1975.01010020815015","article-title":"Clinical experience with a mobile ocular perfusion pump","volume":"93","author":"Ralph","year":"1975","journal-title":"Arch Ophthalmol"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.1780270415","article-title":"Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca","volume":"27","author":"Fox","year":"1984","journal-title":"Arthritis Rheum"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00417-004-1106-5","article-title":"An optimised protocol for the production of autologous serum eyedrops","volume":"243","author":"Liu","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R12-20260422","first-page":"CD009327","article-title":"Autologous serum eye drops for dry eye","volume":"8","author":"Pan","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ophtha.2003.10.019","article-title":"Autologous serum application in the treatment of neurotrophic keratopathy","volume":"111","author":"Matsumoto","year":"2004","journal-title":"Ophthalmology"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.bmt.1703862","article-title":"Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease","volume":"31","author":"Ogawa","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"931","DOI":"10.21873\/invivo.11016","article-title":"Effect of autologous serum eye drops in patients with Sj\u00f6gren syndrome-related dry eye: clinical and in vivo confocal microscopy evaluation of the ocular surface","volume":"30","author":"Semeraro","year":"2016","journal-title":"In Vivo"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/bjo.83.4.390","article-title":"Treatment of dry eye by autologous serum application in Sj\u00f6gren\u2019s syndrome","volume":"83","author":"Tsubota","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"R17-20260422","first-page":"322","article-title":"Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: A retrospective cohort study","volume":"101","author":"Tahmaz","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","article-title":"Autologous serum eye drops for ocular surface disorders","volume":"88","author":"Geerling","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ICO.0000000000000271","article-title":"Long-term use of autologous serum 50% eye drops for the treatment of dry eye disease","volume":"33","author":"Hussain","year":"2014","journal-title":"Cornea"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/bjo.2003.025528","article-title":"A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders","volume":"88","author":"Lagnado","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/02713683.2012.720340","article-title":"Comparison of autologous serum eye drops with different diluents","volume":"38","author":"Cho","year":"2013","journal-title":"Curr Eye Res"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.4103\/IJO.IJO_2756_22","article-title":"Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines","volume":"71","author":"Vazirani","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/ICO.0b013e3182542085","article-title":"Stability of serum eye drops after storage of 6 months","volume":"31","author":"Fischer","year":"2012","journal-title":"Cornea"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/aos.12167","article-title":"Autologous serum eye drops diluted with sodium hyaluronate: Clinical and experimental comparative study","volume":"92","author":"L\u00f3pez-Garc\u00eda","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"R25-20260422","first-page":"CD009327","article-title":"Autologous serum eye drops for dry eye","volume":"2","author":"Pan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"38143.","DOI":"10.1038\/srep38143","article-title":"Undiluted serum eye drops for the treatment of persistent corneal epitheilal defects","volume":"6","author":"Lekhanont","year":"2016","journal-title":"Sci Rep"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/bjo.85.10.1188","article-title":"Autologous serum eyedrops for dry eyes and epithelial defects: Clinical and in vitro toxicity studies","volume":"85","author":"Poon","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R28-20260422","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ophtha.2019.08.018","article-title":"Autologous serum-based eye drops for treatment of ocular surface disease: A report by the American academy of ophthalmology","volume":"127","author":"Shtein","year":"2020","journal-title":"Ophthalmology"},{"key":"R29-20260422","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/15569527.2016.1209770","article-title":"Safety and efficacy of autologous serum eye drop for treatment of dry eyes in graft-versus-host disease","volume":"36","author":"Azari","year":"2017","journal-title":"Cutan Ocul Toxicol"},{"key":"R30-20260422","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.02.009","article-title":"Use of autologous serum tears for the treatment of ocular surface disease from patients with systemic autoimmune diseases","volume":"189","author":"Ali","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R31-20260422","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/bjo.2003.026211","article-title":"Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease","volume":"88","author":"Noble","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R32-20260422","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ajo.2004.08.040","article-title":"The effect of autologous serum eyedrops in the treatment of severe dry eye disease: A prospective randomized case-control study","volume":"139","author":"Kojima","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R33-20260422","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3109\/02713683.2012.674609","article-title":"Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome","volume":"37","author":"Urzua","year":"2012","journal-title":"Curr Eye Res"},{"key":"R34-20260422","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00417-014-2599-1","article-title":"The efficacy of autologous serum eye drops for severe dry eye syndrome: A randomized double-blind crossover study","volume":"252","author":"Celebi","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R35-20260422","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/02713683.2013.824987","article-title":"The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment","volume":"39","author":"Jirsova","year":"2014","journal-title":"Curr Eye Res"},{"key":"R36-20260422","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/ICO.0000000000000542","article-title":"Effectiveness of autologous serum eye drops combined with punctal plugs for the treatment of Sj\u00f6gren Syndrome-related dry eye","volume":"34","author":"Liu","year":"2015","journal-title":"Cornea"},{"key":"R37-20260422","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/ICO.0000000000000147","article-title":"Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary Sj\u00f6gren syndrome","volume":"33","author":"Hwang","year":"2014","journal-title":"Cornea"},{"key":"R38-20260422","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3928\/1081-597X-20060101-13","article-title":"Autologous serum eye drops for dry eye after LASIK","volume":"22","author":"Noda-Tsuruya","year":"2006","journal-title":"J Refract Surg"},{"key":"R39-20260422","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tjo.2015.05.004","article-title":"Autologous serum therapy in recalcitrant laser-assisted in situ keratomileusis-induced neurotrophic epitheliopathy","volume":"5","author":"Lin","year":"2015","journal-title":"Taiwan J Ophthalmol"},{"key":"R40-20260422","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ajo.2010.03.024","article-title":"The effect of topical autologous serum on graft re-epithelialization after penetrating keratoplasty","volume":"150","author":"Chen","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R41-20260422","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00417-018-4068-8","article-title":"Application of autologous serum eye drops after pterygium surgery: A prospective study","volume":"256","author":"Sul","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R42-20260422","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ajo.2006.04.017","article-title":"Autologous serum for the treatment of corneal epithelial abrasions in diabetic patients undergoing vitrectomy","volume":"142","author":"Schulze","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R43-20260422","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1442-9071.2010.02304.x","article-title":"Long-term follow up of autologous serum treatment for recurrent corneal erosions","volume":"38","author":"Ziakas","year":"2010","journal-title":"Clin Exp Ophthalmol"},{"key":"R44-20260422","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00003226-200211000-00010","article-title":"Treatment of recurrent corneal erosions using autologous serum","volume":"21","author":"del Castillo","year":"2002","journal-title":"Cornea"},{"key":"R45-20260422","doi-asserted-by":"crossref","first-page":"826970.","DOI":"10.1155\/2014\/826970","article-title":"Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies","volume":"2014","author":"Semeraro","year":"2014","journal-title":"Biomed Res Int"},{"key":"R46-20260422","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/archophthalmol.2012.1652","article-title":"Use of autologous serum eyedrops for the treatment of ocular surface disease: First US experience in a large population as an insurance-covered benefit","volume":"130","author":"Dalmon","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R47-20260422","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/ICO.0b013e3181a2a7f6","article-title":"Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects","volume":"28","author":"Jeng","year":"2009","journal-title":"Cornea"},{"key":"R48-20260422","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/sj.eye.6700721","article-title":"The use of autologous serum tears in persistent corneal epithelial defects","volume":"18","author":"Young","year":"2004","journal-title":"Eye (Lond)"},{"key":"R49-20260422","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/ICL.0b013e318233c9bb","article-title":"Combined application of autologous serum eye drops and silicone hydrogel lenses for the treatment of persistent epithelial defects","volume":"37","author":"Choi","year":"2011","journal-title":"Eye Contact Lens"},{"key":"R50-20260422","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00417-006-0257-y","article-title":"Combination of serum eye drops with hydrogel bandage contact lenses in the treatment of persistent epithelial defects","volume":"244","author":"Schrader","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R51-20260422","doi-asserted-by":"crossref","first-page":"6600788.","DOI":"10.1155\/2022\/6600788","article-title":"Use of autologous serum eye drops with contact lenses in the treatment of chemical burn-induced bilateral corneal persistent epithelial defects","volume":"2022","author":"Chen","year":"2022","journal-title":"Biomed Res Int"},{"key":"R52-20260422","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.21873\/invivo.12451","article-title":"Treatment of capecitabine corneal side effects with autologous blood-derived serum eye drops","volume":"35","author":"DI Staso","year":"2021","journal-title":"In Vivo"},{"key":"R53-20260422","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ophtha.2007.03.087","article-title":"Autologous serum eyedrops in the treatment of aniridic keratopathy","volume":"115","author":"L\u00f3pez-Garc\u00eda","year":"2008","journal-title":"Ophthalmology"},{"key":"R54-20260422","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/ICO.0000000000002264","article-title":"The use of autologous serum to reverse severe contact lens-induced limbal stem cell deficiency","volume":"39","author":"Yeh","year":"2020","journal-title":"Cornea"},{"key":"R55-20260422","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/ICL.0000000000000951","article-title":"Autologous serum eye drops in the management of limbal stem cell deficiency associated with glaucoma surgery","volume":"49","author":"Niruthisard","year":"2023","journal-title":"Eye Contact Lens"},{"key":"R56-20260422","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9394(14)71962-2","article-title":"Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome","volume":"122","author":"Tsubota","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"R57-20260422","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jtos.2019.01.009","article-title":"Efficacy of autologous serum tears for treatment of neuropathic corneal pain","volume":"17","author":"Aggarwal","year":"2019","journal-title":"Ocul Surf"},{"key":"R58-20260422","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jtos.2015.01.005","article-title":"Autologous serum tears for treatment of photoallodynia in patients with corneal neuropathy: Efficacy and evaluation with in vivo confocal microscopy","volume":"13","author":"Aggarwal","year":"2015","journal-title":"Ocul Surf"},{"key":"R59-20260422","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/sj.bmt.1702334","article-title":"GVHD dry eyes treated with autologous serum tears","volume":"25","author":"Rocha","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R60-20260422","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/tme.13017","article-title":"Reactions to serum eye drops-New Zealand experience and review of the literature","volume":"34","author":"Badami","year":"2024","journal-title":"Transfus Med"},{"key":"R61-20260422","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/archopht.1988.01060140587028","article-title":"Immunoglobulin deposition in the cornea after application of autologous serum","volume":"106","author":"McDonnell","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"R62-20260422","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/OPTH.S15847","article-title":"Fulminant bilateral Haemophilus influenzae keratitis in a patient with hypovitaminosis A treated with contaminated autologous serum","volume":"5","author":"Sanz-Marco","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"R63-20260422","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/02713683.2011.587935","article-title":"Stability of epitheliotrophic factors in autologous serum eye drops from chronic Stevens-Johnson syndrome dry eye compared to non-autoimmune dry eye","volume":"36","author":"Phasukkijwatana","year":"2011","journal-title":"Curr Eye Res"},{"key":"R64-20260422","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-2008-1027199","article-title":"[Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis]","volume":"225","author":"Harloff","year":"2008","journal-title":"Klin Monbl Augenheilkd"},{"key":"R65-20260422","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/tjo.tjo_102_17","article-title":"Serum components and clinical efficacies of autologous serum eye drops in dry eye patients with active and inactive Sjogren syndrome","volume":"7","author":"Ma","year":"2017","journal-title":"Taiwan J Ophthalmol"},{"key":"R66-20260422","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jtos.2020.02.011","article-title":"The role of multisystem disease in composition of autologous serum tears and ocular surface symptom improvement","volume":"18","author":"Ripa","year":"2020","journal-title":"Ocul Surf"},{"key":"R67-20260422","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/tme.12572","article-title":"A retrospective crossover study of autologous and allogeneic serum eye drops for the management of ocular surface disease","volume":"29","author":"Hung","year":"2019","journal-title":"Transfus Med"},{"key":"R68-20260422","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00417-015-3056-5","article-title":"Comparison of epitheliotrophic factors in autologous serum eyedrops from sera of chronic renal failure patients vs. normal controls","volume":"253","author":"Kang","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R69-20260422","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/aos.14788","article-title":"Allogeneic and autologous serum eye drops: A pilot double-blind randomized crossover trial","volume":"99","author":"van der Meer","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"R70-20260422","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.transci.2015.05.014","article-title":"Implementation of a standardised method for the production of allogeneic serum eye drops from regular blood donors in a Norwegian University Hospital: Some methodological aspects and clinical considerations","volume":"53","author":"Espinosa","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"R71-20260422","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1423-0410.2010.01420.x","article-title":"Prevalence of leucocyte antibodies in the Dutch donor population","volume":"100","author":"Middelburg","year":"2011","journal-title":"Vox Sang"},{"key":"R72-20260422","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/aos.12386","article-title":"Ready-made allogeneic ABO-specific serum eye drops: Production from regular male blood donors, clinical routine, safety and efficacy","volume":"92","author":"Harritsh\u00f8j","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"R73-20260422","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/ICO.0b013e3180645cd7","article-title":"Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease","volume":"26","author":"Chiang","year":"2007","journal-title":"Cornea"},{"key":"R74-20260422","doi-asserted-by":"crossref","first-page":"103991.","DOI":"10.1016\/j.transci.2024.103991","article-title":"Allogeneic serum-based eye drops may give better results than autologous drops in Sj\u00f6gren\u2019s syndrome dry eye","volume":"63","author":"Janus","year":"2024","journal-title":"Transfus Apher Sci"},{"key":"R75-20260422","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.transci.2015.05.017","article-title":"Autologous and allogeneic serum eye drops. The Dutch perspective","volume":"53","author":"van der Meer","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"R76-20260422","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/bjophthalmol-2012-301668","article-title":"Allogeneic serum eye drops: Time these became the norm?","volume":"96","author":"Badami","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R77-20260422","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4068\/cmj.2014.50.3.82","article-title":"Use of umbilical cord serum in ophthalmology","volume":"50","author":"Yoon","year":"2014","journal-title":"Chonnam Med J"},{"key":"R78-20260422","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/01.ico.0000183484.85636.b6","article-title":"Application of umbilical cord serum eyedrops for the treatment of dry eye syndrome","volume":"25","author":"Yoon","year":"2006","journal-title":"Cornea"},{"key":"R79-20260422","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bmt.1705566","article-title":"Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease","volume":"39","author":"Yoon","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R80-20260422","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/ICO.0b013e3182580762","article-title":"Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye","volume":"32","author":"Versura","year":"2013","journal-title":"Cornea"},{"key":"R81-20260422","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40123-020-00239-9","article-title":"Umbilical cord blood and serum for the treatment of ocular diseases: A comprehensive review","volume":"9","author":"Giannaccare","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"Suppl 1","key":"R82-20260422","first-page":"s44","article-title":"Cord blood serum-based eye drops: The impact of donor haematological and obstetric factors on the variability of epidermal growth factor levels","volume":"12","author":"Versura","year":"2014","journal-title":"Blood Transfus"},{"key":"R83-20260422","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.transci.2018.06.001","article-title":"Comparison of growth factor and interleukin content of adult peripheral blood and cord blood serum eye drops for cornea and ocular surface diseases","volume":"57","author":"Buzzi","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"R84-20260422","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/bjo.87.11.1312","article-title":"Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects","volume":"87","author":"Vajpayee","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R85-20260422","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1167\/iovs.09-4170","article-title":"Evaluation of umbilical cord serum therapy in acute ocular chemical burns","volume":"52","author":"Sharma","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R86-20260422","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ajo.2007.03.016","article-title":"Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome","volume":"144","author":"Yoon","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R87-20260422","doi-asserted-by":"crossref","first-page":"6750.","DOI":"10.3390\/jcm12216750","article-title":"Allogeneic umbilical cord plasma eyedrops for the treatment of recalcitrant dry eye disease patients","volume":"12","author":"Wong","year":"2023","journal-title":"J Clin Med"},{"key":"R88-20260422","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/bjophthalmol-2019-314859","article-title":"Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: A multicentre randomised cross over clinical trial","volume":"104","author":"Campos","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R89-20260422","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/bjophthalmol-2013-304801","article-title":"Comparative role of 20% cord blood serum and 20% autologous serum in dry eye associated with Hansen\u2019s disease: A tear proteomic study","volume":"99","author":"Mukhopadhyay","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R90-20260422","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.ophtha.2006.12.014","article-title":"Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis","volume":"114","author":"Yoon","year":"2007","journal-title":"Ophthalmology"},{"key":"R91-20260422","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/ICO.0b013e31820d850f","article-title":"Application of umbilical cord serum eyedrops for recurrent corneal erosions","volume":"30","author":"Yoon","year":"2011","journal-title":"Cornea"},{"key":"R92-20260422","first-page":"807","article-title":"Umbilical cord blood serum therapy for the management of persistent corneal epithelial defects","volume":"7","author":"Erdem","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"R93-20260422","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.2147\/OPTH.S385078","article-title":"Treatment of severe dry eye in Stevens-Johnson syndrome with umbilical cord serum eye drops","volume":"16","author":"Susiyanti","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R94-20260422","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/j.1755-3768.2012.02538.x","article-title":"Application of umbilical cord serum eyedrops after laser epithelial keratomileusis","volume":"91","author":"Yoon","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R95-20260422","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/ICL.0000000000000277","article-title":"Evaluation of the role of umbilical cord serum and autologous serum therapy in reepithelialization after keratoplasty: A randomized controlled clinical trial","volume":"43","author":"Kamble","year":"2017","journal-title":"Eye Contact Lens"},{"key":"R96-20260422","doi-asserted-by":"crossref","first-page":"160","DOI":"10.18502\/jovr.v15i2.6732","article-title":"Topical umbilical cord serum for corneal epithelial defects after diabetic vitrectomy","volume":"15","author":"Moradian","year":"2020","journal-title":"J Ophthalmic Vis Res"},{"key":"R97-20260422","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1097\/ICO.0000000000002005","article-title":"In vivo confocal microscopy automated morphometric analysis of corneal subbasal nerve plexus in patients with dry eye treated with different sources of homologous serum eye drops","volume":"38","author":"Giannaccare","year":"2019","journal-title":"Cornea"},{"key":"R98-20260422","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1111\/aos.14953","article-title":"Autologous versus allogeneic versus umbilical cord sera for the treatment of severe dry eye disease: A double-blind randomized clinical trial","volume":"100","author":"Rodr\u00edguez Calvo-de-Mora","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"R99-20260422","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3928\/1081-597X-20070601-13","article-title":"Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma","volume":"23","author":"Alio","year":"2007","journal-title":"J Refract Surg"},{"key":"R100-20260422","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1111\/aos.12710","article-title":"Autologous serum and plasma rich in growth factors in ophthalmology: Preclinical and clinical studies","volume":"93","author":"Anitua","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"R101-20260422","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/bmt.2012.64","article-title":"Autologous platelet lysate for treatment of refractory ocular GVHD","volume":"47","author":"Pezzotta","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R102-20260422","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2174\/138920112800624355","article-title":"The role of \u201ceye platelet rich plasma\u201d (E-PRP) for wound healing in ophthalmology","volume":"13","author":"Alio","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"R103-20260422","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/ICU.0000000000000169","article-title":"Eye platelet-rich plasma in the treatment of ocular surface disorders","volume":"26","author":"Alio","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"R104-20260422","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1120672118818943","article-title":"Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases","volume":"30","author":"Sanchez-Avila","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"R105-20260422","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exer.2013.12.005","article-title":"Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop","volume":"119","author":"Anitua","year":"2014","journal-title":"Exp Eye Res"},{"key":"R106-20260422","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3109\/02713683.2015.1104362","article-title":"Plasma rich in growth factors for the treatment of ocular surface diseases","volume":"41","author":"Anitua","year":"2016","journal-title":"Curr Eye Res"},{"key":"R107-20260422","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/09537104.2016.1143921","article-title":"Implementation of a more physiological plasma rich in growth factor (PRGF) protocol: Anticoagulant removal and reduction in activator concentration","volume":"27","author":"Anitua","year":"2016","journal-title":"Platelets"},{"key":"R108-20260422","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2016.05.023","article-title":"A single-center pilot prospective study of topical application of platelet-derived eye drops for patients with ocular chronic Graft-versus-Host disease","volume":"22","author":"Zallio","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R109-20260422","doi-asserted-by":"crossref","first-page":"24.","DOI":"10.1167\/tvst.9.4.24","article-title":"Characteristics of platelet lysate compared to autologous and allogeneic serum eye drops","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"R111-20260422","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000100933","article-title":"Symptomatic dry eye treatment with autologous platelet-rich plasma","volume":"39","author":"Alio","year":"2007","journal-title":"Ophthalmic Res"},{"key":"R112-20260422","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40123-017-0100-z","article-title":"Treatment of dry eye disease with autologous platelet-rich plasma: A prospective, interventional, non-randomized study","volume":"6","author":"Alio","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"R113-20260422","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1111\/aos.13907","article-title":"Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma","volume":"97","author":"Garc\u00eda-Conca","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"R114-20260422","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jop.2016.0166","article-title":"The effect of immunologically safe plasma rich in growth factor eye drops in patients with Sj\u00f6gren syndrome","volume":"33","author":"Sanchez-Avila","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"R115-20260422","doi-asserted-by":"crossref","first-page":"8406832.","DOI":"10.1155\/2016\/8406832","article-title":"The effect of autologous platelet lysate eye drops: An in vivo confocal microscopy study","volume":"2016","author":"Fea","year":"2016","journal-title":"Biomed Res Int"},{"key":"R116-20260422","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/ICO.0000000000000016","article-title":"Restoration of human lacrimal function following platelet-rich plasma injection","volume":"33","author":"Avila","year":"2014","journal-title":"Cornea"},{"key":"R117-20260422","article-title":"Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye","author":"Avila","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R118-20260422","doi-asserted-by":"crossref","first-page":"e001857.","DOI":"10.1136\/bmjophth-2024-001857","article-title":"Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: A randomised controlled trial","volume":"9","author":"Jongkhajornpong","year":"2024","journal-title":"BMJ Open Ophthalmol"},{"key":"R119-20260422","doi-asserted-by":"crossref","first-page":"19279.","DOI":"10.1038\/s41598-023-46671-2","article-title":"Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sj\u00f6gren\u2019s syndrome: A randomized trial","volume":"13","author":"Kang","year":"2023","journal-title":"Sci Rep"},{"key":"R120-20260422","doi-asserted-by":"crossref","first-page":"8906.","DOI":"10.1038\/s41598-022-12879-x","article-title":"Comparison of epitheliotrophic factors in platelet-rich plasma versus autologous serum and their treatment efficacy in dry eye disease","volume":"12","author":"Metheetrairut","year":"2022","journal-title":"Sci Rep"},{"key":"R121-20260422","doi-asserted-by":"crossref","first-page":"3126.","DOI":"10.3390\/jcm12093126","article-title":"The comparison between the composition of 100% autologous serum and 100% platelet-rich plasma eye drops and their impact on the treatment effectiveness of dry eye disease in primary Sjogren syndrome","volume":"12","author":"Wr\u00f3bel-Dudzi\u0144ska","year":"2023","journal-title":"J Clin Med"},{"key":"R122-20260422","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2016.221","article-title":"Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD","volume":"52","author":"Pezzotta","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R123-20260422","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ophtha.2006.10.044","article-title":"Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers","volume":"114","author":"Alio","year":"2007","journal-title":"Ophthalmology"},{"key":"R124-20260422","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/ICO.0b013e3182114661","article-title":"Topical autologous platelet-rich plasma eyedrops for acute corneal chemical injury","volume":"31","author":"Panda","year":"2012","journal-title":"Cornea"},{"key":"R125-20260422","doi-asserted-by":"crossref","first-page":"3538764","DOI":"10.1155\/2018\/3538764","article-title":"Clinical efficacy of platelet-rich plasma in the treatment of neurotrophic corneal ulcer","volume":"2018","author":"Wr\u00f3bel-Dudzi\u0144ska","year":"2018","journal-title":"J Ophthalmol"},{"key":"R126-20260422","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s10384-012-0175-y","article-title":"Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis","volume":"56","author":"Kim","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"R127-20260422","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/ICO.0b013e3181a81820","article-title":"Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects","volume":"29","author":"L\u00f3pez-Plandolit","year":"2010","journal-title":"Cornea"},{"key":"R128-20260422","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s10792-018-0968-1","article-title":"Platelet lysate promotes re-epithelialization of persistent epithelial defects: A pilot study","volume":"39","author":"Abu-Ameerh","year":"2019","journal-title":"Int Ophthalmol"},{"key":"R129-20260422","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1120672117747042","article-title":"Treatment with platelet-rich plasma of surgically related dormant corneal ulcers","volume":"28","author":"Alio","year":"2018","journal-title":"Eur J Ophthalmol"},{"key":"R130-20260422","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.survophthal.2003.10.004","article-title":"The amniotic membrane in ophthalmology","volume":"49","author":"Dua","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"R131-20260422","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/OPTH.S165553","article-title":"Amniotic membrane extract and eye drops: A review of literature and clinical application","volume":"12","author":"Murri","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R132-20260422","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.284571","article-title":"Safety and efficacy of human amniotic epithelial stem cell eye drops in ocular chronic graft-versus-host disease","author":"Cheng","year":"2024","journal-title":"Haematologica"},{"key":"R133-20260422","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10561-016-9572-7","article-title":"Collection and characterization of amniotic fluid from scheduled C-section deliveries","volume":"17","author":"Pierce","year":"2016","journal-title":"Cell Tissue Bank"},{"key":"R134-20260422","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/j.jcrs.0000000000001100","article-title":"Phase I\/II randomized, double-masked, placebo-controlled study of processed amniotic fluid drops after PRK","volume":"49","author":"Ip","year":"2023","journal-title":"J Cataract Refract Surg"},{"key":"R135-20260422","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jtos.2017.11.001","article-title":"The role of amniotic membrane extract eye drop (AMEED) in in vivo cultivation of limbal stem cells","volume":"16","author":"Baradaran-Rafii","year":"2018","journal-title":"Ocul Surf"},{"key":"R136-20260422","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/112067210501500403","article-title":"Suspension made with amniotic membrane: Clinical trial","volume":"15","author":"Bonci","year":"2005","journal-title":"Eur J Ophthalmol"},{"key":"R137-20260422","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s10792-021-01856-4","article-title":"Amniotic membrane extract eye drops for ocular surface diseases: Use and clinical outcome in real-world practice","volume":"41","author":"Sabater-Cruz","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R138-20260422","doi-asserted-by":"crossref","first-page":"9.","DOI":"10.1167\/tvst.5.3.9","article-title":"Morselized amniotic membrane tissue for refractory corneal epithelial defects in cicatricial ocular surface diseases","volume":"5","author":"Cheng","year":"2016","journal-title":"Transl Vis Sci Technol"},{"key":"R139-20260422","first-page":"314","article-title":"Amniotic membrane extract preparation: What is the best method?","volume":"9","author":"Mahbod","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"R140-20260422","first-page":"459","article-title":"Amniotic membrane extract eye drop promotes limbal stem cell proliferation and corneal epithelium healing","volume":"20","author":"Shayan Asl","year":"2019","journal-title":"Cell J"},{"key":"R141-20260422","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10561-021-09962-4","article-title":"Amniotic membrane extract eye drops: A new approach to severe ocular surface pathologies","volume":"23","author":"P\u00e9rez","year":"2022","journal-title":"Cell Tissue Bank"},{"issue":"Suppl 1","key":"R142-20260422","first-page":"161","article-title":"Application of the amniotic membrane extract (AMX) for the persistent epithelial defect (PED) of the cornea","volume":"37","author":"Kordi\u0107","year":"2013","journal-title":"Coll Antropol"},{"key":"R143-20260422","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/OPTH.S203510","article-title":"Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease","volume":"13","author":"Yeu","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R144-20260422","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1442-9071.2009.02159.x","article-title":"Amniotic membrane extraction solution for ocular chemical burns","volume":"37","author":"Liang","year":"2009","journal-title":"Clin Exp Ophthalmol"},{"key":"R145-20260422","first-page":"217","article-title":"The effect of amniotic membrane extracted eye drop on repairing the corneal epithelial in patients after trans-epithelial photorefractive keratectomy: An interventional and historical study","volume":"25","author":"Ranaei","year":"2023","journal-title":"Cell J"},{"key":"R146-20260422","first-page":"81","article-title":"A pilot study of the short term effectiveness and safety of amniotic fluid in severe dry eye disease","volume":"8","author":"Chen","year":"2019","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"R147-20260422","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/ICO.0000000000003474","article-title":"One-year results of a phase I\/II randomized, double-masked, placebo-controlled study of processed amniotic fluid drops after PRK","volume":"43","author":"Kirschenbaum","year":"2024","journal-title":"Cornea"},{"key":"R148-20260422","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","article-title":"Topical recombinant human nerve growth factor (Cenegermin) for neurotrophic keratopathy: A multicenter randomized vehicle-controlled pivotal trial","volume":"127","author":"Pflugfelder","year":"2020","journal-title":"Ophthalmology"},{"key":"R149-20260422","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s10792-022-02245-1","article-title":"TNF-\u03b1 inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China","volume":"42","author":"Dong","year":"2022","journal-title":"Int Ophthalmol"},{"key":"R150-20260422","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ymthe.2017.04.020","article-title":"Hepatocyte growth factor suppresses inflammation and promotes epithelium repair in corneal injury","volume":"25","author":"Omoto","year":"2017","journal-title":"Mol Ther"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_482_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:58:15Z","timestamp":1786647495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_482_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_482_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"2025-02-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}